Background Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic
valve, but lipid-lowering studies have had conflicting results. Methods We conducted a …

Background— Retrospective studies have suggested that patients with a low transvalvular
gradient in the presence of an aortic valve area <1.0 cm 2 and normal ejection fraction may …

Background and aims Low-density lipoprotein cholesterol (LDL-C) is a major contributor to
cardiovascular disease. In the Dyslipidemia International Study II (DYSIS II), we determined …

Background and aims There is an inconsistency between international guidelines on lipid-lowering
treatment regarding whether to pursue LDL-C treatment targets or to focus on the …

Background Patients with coronary heart disease (CHD) and survivors of acute coronary
syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low-density …

Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular
disease: each 1.0 mmol/L (38.7 mg/dL) reduction in LDL-C reduces the incidence of major …

Background Therapeutic intervention with low-density lipoprotein cholesterol-lowering agents
known as statins has been demonstrated to reduce cardiovascular risk. However, many …

Background As mortality due to cardiovascular disease increases throughout the world,
accurate data on risk factors such as hyperlipidemia are required. This is lacking in the Asia-…

In the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, combined ezetimibe (10 mg)
and simvastatin (40 mg) decreased low-density lipoprotein cholesterol levels by 50% and …

Hypercholesterolemic patients (n = 1,547) at high atherosclerotic cardiovascular disease
risk with low-density lipoprotein cholesterol (LDL-C) levels ≥100 and ≤160 mg/dl while …